Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour

Authors

  • Neil Pugashetti Department of Urology, University of California, Davis, Sacramento, CA
  • Stanley A. Yap Department of Urology, University of California, Davis, Sacramento, CA
  • Primo N. Lara Jr. Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, CA
  • Regina Gandour-Edwards Department of Pathology, University of California, Davis, Sacramento, CA
  • Marc Dall'Era Department of Urology, University of California, Davis, Sacramento, CA

DOI:

https://doi.org/10.5489/cuaj.2447

Keywords:

signet-ring cell carcinoma, FOLFOX-6, bladder cancer, metastatic, next generation sequencing

Abstract

Primary signet-ring cell carcinoma (SRCC) of the urinary bladder, a variant of adenocarcinoma, is exceedingly rare and as a result no gold standard exists for its management. We report a case of primary SRCC of the bladder with recurrent metastases; we utilized an innovative diagnostic approach and the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy.

Downloads

Download data is not yet available.

Author Biographies

Neil Pugashetti, Department of Urology, University of California, Davis, Sacramento, CA

Medical Student Research Fellow, Department of Urology, University of California, Davis School of Medicine

Stanley A. Yap, Department of Urology, University of California, Davis, Sacramento, CA

Assistant Professor, Urologic Oncology, Department of Urology

Primo N. Lara Jr., Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, CA

Professor, Division of Hematology and Oncology, Department of Internal Medicine. Associate Director of Translational Research, UC Davis Comprehensive Cancer Center. Co-Leader of the Cancer Therapeutics Program, UC Davis Comprehensive Cancer Center.

Regina Gandour-Edwards, Department of Pathology, University of California, Davis, Sacramento, CA

Professor, Vice Chair of Education, Department of Pathology & Laboratory Medicine

Marc Dall'Era, Department of Urology, University of California, Davis, Sacramento, CA

Assistant Professor of Urologic Oncology and Vice Chair of Urology, Department of Urology

Downloads

Published

2015-04-13

How to Cite

Pugashetti, N., Yap, S. A., Lara Jr., P. N., Gandour-Edwards, R., & Dall’Era, M. (2015). Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Canadian Urological Association Journal, 9(3-4), E204–7. https://doi.org/10.5489/cuaj.2447

Issue

Vol. 9 No. 3-4 (2015): CUAJ April

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.